Research Analysts Offer Predictions for CRBU FY2030 Earnings

Caribou Biosciences, Inc. (NASDAQ:CRBU) – Equities research analysts at Brookline Capital Management issued their FY2030 earnings per share (EPS) estimates for Caribou Biosciences in a research report issued to clients and investors on Wednesday, February 4th. Brookline Capital Management analyst L. Cann forecasts that the company will post earnings per share of ($5.28) for the year. The consensus estimate for Caribou Biosciences’ current full-year earnings is ($1.64) per share.

Caribou Biosciences (NASDAQ:CRBU) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.06. Caribou Biosciences had a negative return on equity of 69.85% and a negative net margin of 1,690.45%.The firm had revenue of $2.20 million during the quarter, compared to the consensus estimate of $1.94 million.

A number of other analysts have also issued reports on CRBU. Citigroup lifted their price target on shares of Caribou Biosciences from $5.00 to $8.00 and gave the stock a “buy” rating in a research note on Monday, November 3rd. Truist Financial set a $7.00 target price on shares of Caribou Biosciences in a research note on Tuesday, November 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Caribou Biosciences in a research note on Wednesday, January 21st. Finally, HC Wainwright boosted their price objective on Caribou Biosciences from $3.00 to $9.00 and gave the company a “buy” rating in a report on Wednesday, November 5th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $8.00.

Caribou Biosciences Stock Down 8.6%

Shares of CRBU opened at $1.48 on Friday. The firm has a market cap of $138.34 million, a price-to-earnings ratio of -0.87 and a beta of 2.61. The business’s 50 day moving average is $1.65 and its two-hundred day moving average is $1.94. Caribou Biosciences has a 52-week low of $0.66 and a 52-week high of $3.54.

Institutional Trading of Caribou Biosciences

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Envestnet Asset Management Inc. grew its position in shares of Caribou Biosciences by 626.8% during the second quarter. Envestnet Asset Management Inc. now owns 318,657 shares of the company’s stock worth $402,000 after acquiring an additional 274,812 shares during the last quarter. Aberdeen Group plc boosted its stake in Caribou Biosciences by 118.3% during the 2nd quarter. Aberdeen Group plc now owns 897,579 shares of the company’s stock valued at $1,131,000 after purchasing an additional 486,435 shares during the period. Y Intercept Hong Kong Ltd bought a new position in Caribou Biosciences in the 2nd quarter worth about $173,000. Savant Capital LLC acquired a new stake in shares of Caribou Biosciences in the second quarter valued at approximately $36,000. Finally, Catalyst Funds Management Pty Ltd bought a new stake in shares of Caribou Biosciences during the second quarter valued at approximately $49,000. 77.51% of the stock is currently owned by institutional investors and hedge funds.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc is a clinical-stage biopharmaceutical company that leverages its proprietary CRISPR-Cas gene-editing platform to develop transformative cell therapies and in vivo treatments for a range of cancers and genetic diseases. The company’s core technology enables precise modification of cellular genomes, allowing the design of engineered T-cell and NK-cell therapies aimed at improving safety, efficacy and persistence in patients with hematologic and solid tumor malignancies. Alongside its oncology portfolio, Caribou is advancing in vivo editing programs targeting monogenic disorders, with initiatives in areas such as Duchenne muscular dystrophy and familial amyloidosis.

Established in 2011 and headquartered in Berkeley, California, Caribou Biosciences was co-founded by Nobel laureate Jennifer Doudna, one of the pioneers of CRISPR gene-editing technology.